BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Cerilliant
Argus Health
Johnson and Johnson
Merck
Deloitte
Harvard Business School
Fish and Richardson
Medtronic
Dow

Generated: January 22, 2018

DrugPatentWatch Database Preview

SEROQUEL XR Drug Profile

« Back to Dashboard

When do Seroquel Xr patents expire, and when can generic versions of Seroquel Xr launch?

Seroquel Xr is a drug marketed by Astrazeneca and is included in one NDA. There is one patent protecting this drug and four Paragraph IV challenges.

The generic ingredient in SEROQUEL XR is quetiapine fumarate. There are fifty-two drug master file entries for this compound. Fifty-two suppliers are listed for this compound. Additional details are available on the quetiapine fumarate profile page.
Drug patent expirations by year for SEROQUEL XR
Pharmacology for SEROQUEL XR
Medical Subject Heading (MeSH) Categories for SEROQUEL XR

US Patents and Regulatory Information for SEROQUEL XR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca SEROQUEL XR quetiapine fumarate TABLET, EXTENDED RELEASE;ORAL 022047-001 May 17, 2007 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Astrazeneca SEROQUEL XR quetiapine fumarate TABLET, EXTENDED RELEASE;ORAL 022047-003 May 17, 2007 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Astrazeneca SEROQUEL XR quetiapine fumarate TABLET, EXTENDED RELEASE;ORAL 022047-005 Aug 11, 2008 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Astrazeneca SEROQUEL XR quetiapine fumarate TABLET, EXTENDED RELEASE;ORAL 022047-002 May 17, 2007 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Astrazeneca SEROQUEL XR quetiapine fumarate TABLET, EXTENDED RELEASE;ORAL 022047-004 May 17, 2007 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for SEROQUEL XR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astrazeneca SEROQUEL XR quetiapine fumarate TABLET, EXTENDED RELEASE;ORAL 022047-004 May 17, 2007 ➤ Subscribe ➤ Subscribe
Astrazeneca SEROQUEL XR quetiapine fumarate TABLET, EXTENDED RELEASE;ORAL 022047-001 May 17, 2007 ➤ Subscribe ➤ Subscribe
Astrazeneca SEROQUEL XR quetiapine fumarate TABLET, EXTENDED RELEASE;ORAL 022047-003 May 17, 2007 ➤ Subscribe ➤ Subscribe
Astrazeneca SEROQUEL XR quetiapine fumarate TABLET, EXTENDED RELEASE;ORAL 022047-002 May 17, 2007 ➤ Subscribe ➤ Subscribe
Astrazeneca SEROQUEL XR quetiapine fumarate TABLET, EXTENDED RELEASE;ORAL 022047-004 May 17, 2007 ➤ Subscribe ➤ Subscribe
Astrazeneca SEROQUEL XR quetiapine fumarate TABLET, EXTENDED RELEASE;ORAL 022047-002 May 17, 2007 ➤ Subscribe ➤ Subscribe
Astrazeneca SEROQUEL XR quetiapine fumarate TABLET, EXTENDED RELEASE;ORAL 022047-001 May 17, 2007 ➤ Subscribe ➤ Subscribe
Astrazeneca SEROQUEL XR quetiapine fumarate TABLET, EXTENDED RELEASE;ORAL 022047-005 Aug 11, 2008 ➤ Subscribe ➤ Subscribe
Astrazeneca SEROQUEL XR quetiapine fumarate TABLET, EXTENDED RELEASE;ORAL 022047-005 Aug 11, 2008 ➤ Subscribe ➤ Subscribe
Astrazeneca SEROQUEL XR quetiapine fumarate TABLET, EXTENDED RELEASE;ORAL 022047-003 May 17, 2007 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for SEROQUEL XR
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Extended-release Tablets 150 mg ➤ Subscribe 11/17/2008
➤ Subscribe Extended-release Tablets 50 mg ➤ Subscribe 10/17/2008
➤ Subscribe Extended-release Tablets 400 mg ➤ Subscribe 6/18/2008
➤ Subscribe Tablets 200 mg and 300 mg ➤ Subscribe 6/12/2008

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
AstraZeneca
Merck
QuintilesIMS
US Department of Justice
Argus Health
Harvard Business School
Johnson and Johnson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot